Acciones Evotec SE Other OTC
Acciones
EVTCY
US30050E1055
Biotecnología e investigación médica
Ventas 2024 * | 883 M 944 M | Ventas 2025 * | 1037,65 M 1109,69 M | Capitalización | 1503,44 M 1607,81 M |
---|---|---|---|---|---|
Resultado Neto 2024 * | -28 M -29,94 M | Resultado Neto 2025 * | 31 M 33,15 M | VE / Ventas 2024 * | 1,96 x |
Deuda neta 2024 * | 227 M 243 M | Deuda neta 2025 * | 186 M 199 M | VE / Ventas 2025 * | 1,63 x |
P/E ratio 2024 * |
-54,3
x | P/E ratio 2025 * |
32
x | Empleados | - |
Rendimiento 2024 * |
-
| Rendimiento 2025 * |
-
| Flotante | 90,64 % |
Último transcript sobre Evotec SE
Directores | Puesto | Edad | Desde |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19/06/19 |
Laetitia Rouxel
DFI | Director of Finance/CFO | 51 | 07/02/23 |
Craig Johnstone
COO | Chief Operating Officer | 54 | 01/05/12 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19/06/19 |
Roland Sackers
BRD | Director/Board Member | 56 | 19/06/19 |
Chairman | 63 | 17/06/14 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+21,85 % | 46,93 mil M | |
+37,63 % | 39,08 mil M | |
-8,05 % | 38,48 mil M | |
+29,04 % | 31,01 mil M | |
-13,75 % | 26,14 mil M | |
+10,65 % | 25,88 mil M | |
+38,43 % | 12,53 mil M | |
-6,92 % | 11,36 mil M | |
-12,29 % | 10,65 mil M |